You are here

Article Text

Article menu
Download PDFPDF
Leading article
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye

https://doi.org/10.1136/gutjnl-2012-302910

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors The manuscript has been written by both authors. No professional or additional help has been sought or obtained.

    • Competing interests GD: Vertex, Abbott, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pharmasett, Pfizer, Roche/Genentech, Merck, Tibotec, Astek, Achillion, Janssen: Advisory Board; Bristol Myers, Gilead Sciences, Human Genome Sciences, Presidio: Advisory board/Safety Monitoring Board; Zymogenetics: Safety Monitoring Board.

    • Provenance and peer review Commissioned; internally peer reviewed.